TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01049178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Silymarin
Description: Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Silymarin, maintenance dose
Description: The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01602393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day in the morning for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 2x, once a day in the morning for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 3x
Description: oral tablet, 3x, once a day in the morning for 48 weeks
Study: NCT01609452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blisibimod

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02873338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium
Description: Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
Study: NCT04292314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil
Description: Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honey
Description: Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
Study: NCT02386826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
Study: NCT02508909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videoscopic ilioinguinal dissection
Description: Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
Study: NCT04499287

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 15-minute walk at preferred walking speed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-minute walk at preferred walking speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15-minute walk at preferred walking speed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber
Description: 9 grams soluble fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber
Description: 9 grams soluble fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: 9 grams soluble fiber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: control
Study: NCT03534375

Intervention type: OTHER
Intervention: The study is an observational cross sectional study
Description: An intervention will not be performed

Intervention type: OTHER
Intervention: The study is an observational cross sectional study
Description: An intervention will not be performed
Study: NCT03705429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TC-H x Paclitaxel (P) + Trastuzumab(T)
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC-H x Paclitaxel (P) + Trastuzumab(T)
Description: chemotherapy
Study: NCT04592146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frailty multicomponent intervention supported by POSITIVE
Description: This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frailty multicomponent intervention
Description: This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty multicomponent intervention
Description: This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
Study: NCT01551030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
Study: NCT03778138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus Pemetrexed
Description: Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
Study: NCT04328701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Behavioral Therapy
Description: Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
Study: NCT02795559

Intervention type: OTHER
Group type: OTHER
Intervention: Inulin
Description: 75g glucose plus 24g inulin dissolved in 300ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Inulin
Description: 75g glucose plus 24g inulin dissolved in 300ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Resistant starch
Description: 75g glucose plus 28g resistant starch in 300ml water

Intervention type: OTHER
Group type: OTHER
Intervention: Resistant starch
Description: 75g glucose plus 28g resistant starch in 300ml water
Study: NCT03903627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: verbal instruction
Description: Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
Study: NCT00297037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus 1% cream
Description: pimecrolimus cream or matching placebo BID for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimecrolimus 1% cream
Description: pimecrolimus cream or matching placebo BID for 6 weeks
Study: NCT00581776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
Study: NCT02376023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Text and voice messages sent to study participants reminding them to schedule a PAP smear.
Study: NCT00581776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1 mg administered by IV on day 3 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally on days 1-4 of each cycle.
Study: NCT04922918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligilactobacillus salivarius MP101
Description: Administration of the strain through a fermented milk
Study: NCT03503903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet Cupping
Description: CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
Study: NCT02327858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive text messages
Description: Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
Study: NCT04471636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings ScanWatch
Description: The smart watch is capable of recording SpO2, ECG, and heart rate.
Study: NCT02523846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient re-education
Description: A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient re-education
Description: A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
Study: NCT04582955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide in combination with chemotherapy
Description: Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
Study: NCT02929459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin Dose 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin Dose 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04378114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.
Description: Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.
Description: Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetominophen
Description: One time administration of acetaminophen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetominophen
Description: One time administration of acetaminophen.
Study: NCT01832532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
Study: NCT03057652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk
Description: ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours.
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.

Intervention type: DRUG
Group type: OTHER
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.

Intervention type: DRUG
Group type: OTHER
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.

Intervention type: DRUG
Group type: OTHER
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.
Study: NCT02208830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
Study: NCT03020030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: Only for patients with Pegaspargase allergy or silent inactivation.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Standard of Care
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care
Study: NCT02208830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional program
Description: The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
Study: NCT03020030

Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: CYTARABINE
Description: Standard of Care
Study: NCT02396719

Intervention type: DEVICE
Intervention: LenSx® Laser
Description: Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
Study: NCT02121652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy eating control
Description: Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
Study: NCT00770328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400mg PO TID x 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO TID x 8 weeks